Klaus Lindpaintner

Dr. Klaus Lindpaintner

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 1991 in Cell
Verified
Journal Article
Closed access
HJHoward J. Jacob
Howard J. Jacob
KLKlaus Lindpaintner
Klaus Lindpaintner
SLStephen E. Lincoln
Stephen E. Lincoln
KKKenro Kusumi
Kenro Kusumi
RBRuth K. Bunker
Ruth K. Bunker
ELEric S. Lander
Eric S. Lander

7 March 2022 in Viruses
Verified
Journal Article
Open access
PDF file
CPChad E Pickering
Chad E Pickering
BZBo Zhou
Bo Zhou
GXGege Xu
Gege Xu
RRRachel Rice
Rachel Rice
PRPrasanna Ramachandran
Prasanna Ramachandran
KLKlaus Lindpaintner
Klaus Lindpaintner
Glycosylation is the most common form of post-translational modification of proteins, critically affecting their structure and function. Using liquid chromatography and mass spectrometry for high-resolution site-specific quantification of glycopeptides coupled with high-throughput artificial intelligence-powered data processing, we analyzed differential protein glycoisoform distributions of 597 abundant serum glycopeptides and nonglycosylated peptides in 50 individuals who had been seriously ill with COVID-19 and in 22 individuals who had recovered after an asymptomatic course of COVID-19. As additional comparison reference phenotypes, we included 12 individuals with a history of infection with a common cold coronavirus, 16 patients with bacterial sepsis, and 15 healthy subjects without history of coronavirus exposure. We found statistically significant differences, at FDR < 0.05, for normalized abundances of 374 of the 597 peptides and glycopeptides interrogated between symptomatic and asymptomatic COVID-19 patients. Similar statistically significant differences were seen when comparing symptomatic COVID-19 patients to healthy controls (350 differentially abundant peptides and glycopeptides) and common cold coronavirus seropositive subjects (353 differentially abundant peptides and glycopeptides). Among healthy controls and sepsis patients, 326 peptides and glycopeptides were found to be differentially abundant, of which 277 overlapped with biomarkers that showed differential expression between symptomatic COVID-19 cases and healthy controls. Among symptomatic COVID-19 cases and sepsis patients, 101 glycopeptide and peptide biomarkers were found to be statistically significantly abundant. Using both supervised and unsupervised machine learning techniques, we found specific glycoprotein profiles to be strongly predictive of symptomatic COVID-19 infection. LASSO-regularized multivariable logistic regression and K-means clustering yielded accuracies of 100% in an independent test set and of 96% overall, respectively. Our findings are consistent with the interpretation that a majority of glycoprotein modifications observed which are shared among symptomatic COVID-19 and sepsis patients likely represent a generic consequence of a severe systemic immune and inflammatory state. However, there are glycoisoform changes that are specific and particular to severe COVID-19 infection. These may be representative of either COVID-19-specific consequences or susceptibility to or predisposition for a severe course of the disease. Our findings support the potential value of glycoproteomic biomarkers in the biomedical understanding and, potentially, the clinical management of serious acute infectious conditions.

1 July 2001 in Human Heredity
Verified
Journal Article
Open access
PDF file
JHJian Huang
Jian Huang
YJYanming Jiang
Yanming Jiang
JMJason H. Moore
Jason H. Moore
LJL.B. Jorde
L.B. Jorde
KSKimberly D. Siegmund
Kimberly D. Siegmund
PTPatricia N. Tonin
Patricia N. Tonin

5 April 2022 in medRxiv
Verified
Preprint
Open access
PDF file
KMKaitlynn Moser
Kaitlynn Moser
MSMichelle Soto
Michelle Soto
DGDaniela Geba
Daniela Geba
PAPaul Allen
Paul Allen
KLKlaus Lindpaintner
Klaus Lindpaintner
Background Immune checkpoint inhibitors (ICIs) are a valuable treatment option for patients with malignant tumors, but only selected patients respond to ICIs. Available biomarkers are of limited use in guiding ICI therapy. Objective To examine clinicians’ perspective on the use of ICIs and biomarkers for treatment of malignant tumors and to identify unmet needs related to their use. Methods We conducted in-depth telephone interviews of eight oncologists, and 100 oncologists completed online surveys. Results Oncologists have a positive attitude toward use of ICIs, and 98% of them prescribe them in all approved indications. Clinicians report that only about half of the patients with solid tumors responded to treatment, overestimated the response rate to ICIs across most types of tumors they treat compared with data in the literature. They ranked the lack of reliability of biomarkers to guide treatment (rating of 4.4 out of 7) as the top challenge with use of ICIs, followed by lack of overall efficacy and toxicity or occurrence of immune-related adverse events. The biomarkers most often used by survey participants were: a comprehensive panel including driver mutations and tumor mutational burden(69% of respondents), programmed cell death ligand-1 (PD-L1) expression (62%), and microsatellite instability (MSI) (56%). Oncologists indicated that they ordered biomarkers for each type of cancer according to their perceived usefulness of each biomarker in predicting the outcomes for ICI therapy, being more likely to use those perceived as useful or very useful. Conclusion Clinicians indicate that more reliable therapy-response prediction biomarkers would have a great impact on treatment decisions for patients with solid tumors, reducing unnecessary treatments, side effects, and health care expenditures.